Engflag

Abilify Mycite

Quick links to important sections

Abilify Mycite

Selected form

Abilify Mycite_EN

Treatment option: Bipolar Disorder, Fits, Schizophrenia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Abilify Mycite

Abilify Mycite is a unique, prescription-only therapeutic product. It holds the distinction of being the first digital medicine system approved in the United States, classified as a drug-device combination product due to its integrated technology for digitally recording medication ingestion.

Property Description
Active ingredient Aripiprazole (INN)
Form Oral Tablets with Sensor
Pharmacological class Atypical Antipsychotic (Second Generation)
General Purpose Digital tracking of ingestion to support adherence
Manufacturer Otsuka Pharmaceutical Co., Ltd.

Abilify Mycite: A Definition and Drug Class

The pharmaceutical core of the system is the active ingredient, Aripiprazole (INN), a synthetic chemical entity that functions as an Atypical Antipsychotic. Aripiprazole is clinically recognized for its role in helping to stabilize certain mental health conditions, such as schizophrenia and bipolar I disorder. The mechanism of Aripiprazole involves modulating the activity of chemical messengers in the brain. Aripiprazole acts as a partial agonist at specific dopamine and serotonin receptors.

The Unique Digital Medicine System Composition

Abilify Mycite is distinct because it is an Oral Tablet with Sensor designed for oral administration. The tablet contains the Aripiprazole medication and an embedded Ingestible Event Marker (IEM) sensor, a component made of materials commonly found in food. This differentiates it from generic Aripiprazole tablets.

The complete system includes the sensor-embedded tablet, the Mycite Patch (a wearable sensor), and the Mycite App (a compatible smartphone application). This system allows for the detection and recording of the date and time of the ingestion event, transmitted from the patch to the app.

Purpose of the Digital Tracking Feature

The foundational objective of this technology is the objective measurement of medication ingestion. This unique tracking feature is designed to support patient-physician collaboration by providing verifiable data on whether the tablet was swallowed, which is crucial where medication adherence is a challenge. However, it must be noted that the ability of the product to improve patient compliance with their treatment regimen has not been established.

Regulatory References

  1. NIH PMC5725548 (Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity)

What side effects are possible with Abilify Mycite?

The safety profile of the aripiprazole component of Abilify Mycite is based on official government regulatory documents which classify associated adverse reactions and note critical safety considerations.

Adverse Reaction Scope

Classification Examples of Officially Documented Effects
Common (Affects up to 1 in 10 patients) Nausea, vomiting, constipation, headache, dizziness, insomnia, restlessness, anxiety, blurred vision, and weight gain. Extrapyramidal symptoms (EPS) and akathisia (a state of internal restlessness) are frequently reported.
System-Organ Classes Effects are grouped by physiological systems including Nervous System Disorders, Gastrointestinal Disorders, Psychiatric Disorders, and Metabolic and Nutrition Disorders.

Serious Adverse Reactions

The most serious safety concerns are highlighted in the regulatory labeling:

  • Increased Mortality in Elderly Patients: Atypical antipsychotics are associated with an increased risk of death when used in older adults with dementia-related psychosis. The medicine is not approved for this population.
  • Suicidal Thoughts and Behaviors (Suicidality): An increased risk is noted in children, adolescents, and young adults when used as an adjunctive treatment for Major Depressive Disorder.
  • Other Serious Risks: These include Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (uncontrollable movements), and significant Metabolic Changes such as hyperglycemia, dyslipidemia, and body weight gain.

Population-Specific Notes and Limitations

Safety constraints noted in official labeling include caution for patients with a history of seizures or with conditions that lower the seizure threshold. Orthostatic hypotension (low blood pressure upon standing) is noted, particularly for patients with known cardiovascular or cerebrovascular disease. Akathisia is noted as being more frequent at the start of treatment or during dose escalation.

Overdose and Emergency Response

Overdose scope

Feature Official Regulatory Statements
Documented overdose presentations Overdose symptoms reported include vomiting, somnolence, and tremor [FDA]. Other documented manifestations are lethargy, confusional state, mydriasis (dilated pupils), and extrapyramidal symptoms (EPS) [SmPC].
Physiological systems affected CNS effects (e.g., depressed level of consciousness, coma, convulsion, status epilepticus); Cardiovascular effects (e.g., tachycardia, hypotension, QT interval prolongation); Metabolic/Muscular effects (e.g., acidosis, increased Blood Creatine Phosphokinase [CPK], increased Aspartate Aminotransferase [AST]) [FDA, SmPC].
Dose-related or exposure-related factors Accidental overdose in children (age 12 and younger) has been reported with ingestions up to 195 mg with no reported fatalities [FDA].
Population-specific overdose notes In pediatric cases, signs typically included somnolence, transient loss of consciousness, and EPS [FDA].
Emergency-response statements Management should concentrate on supportive therapy and the maintenance of an adequate airway, oxygenation, and ventilation [FDA]. The possibility of multiple medicinal product involvement must be considered [SmPC].
When immediate medical help is required In the event of over-exposure, patients must seek immediate medical attention and call a poison control center [FDA]. Close medical supervision and monitoring should continue until the patient recovers [SmPC].

Overdose classifications (high-level)

Feature Official Regulatory Statements
Severity classification Outcomes range from common findings (vomiting, somnolence) to serious outcomes (coma, respiratory arrest) [FDA, SmPC].
Regulatory basis FDA Prescribing Information and EMA/national Summary of Product Characteristics (SmPC) [FDA, SmPC].
Overdose-context constraints No specific antidote is known for aripiprazole overdosage [FDA]. Haemodialysis is considered unlikely to be useful due to the high protein binding of the active ingredient [SmPC].

Resulting overdose structure

Official overdose statements:

  • The official label lists somnolence, tremor, and vomiting as commonly reported manifestations of overdosage.
  • Life-threatening manifestations documented in regulatory sources include coma, status epilepticus, respiratory arrest, and significant QT interval prolongation.
  • An Electrocardiogram (ECG) must be obtained in case of overdosage, and cardiac monitoring should be instituted if signs of QT interval prolongation are observed.
  • Regulatory authorities mandate that in the event of over-exposure, a patient must call a poison control center and receive management focused on supportive therapy and the maintenance of an adequate airway.

Connection to the overall overdose profile: Regulatory documents define the overdose profile primarily through a detailed listing of neurological and cardiovascular manifestations that signal the need for urgent intervention. The profile explicitly structures the required help-seeking conditions by mandating immediate contact with medical professionals and emphasizing the need for continuous observation and supportive treatment due to the absence of a specific antidote.

Therapeutic Uses of Abilify Mycite

The medication is commonly used to help with symptomatic relief and stability in conditions associated with acute or disruptive episodes. Its use is relevant in clinical settings that involve acute or unstable symptom patterns, specifically for: Schizophrenia, Bipolar I Disorder, and Major Depressive Disorder (MDD) as an adjunctive treatment.

Symptom Management and Stability

This medication is applied across domains where additional symptomatic support is needed, primarily to manage symptom clusters that may become intense or disruptive, such as hallucinations and delusions. In conditions involving episodic or fluctuating manifestations like Bipolar I Disorder, it assists in easing symptoms associated with acute or episodic changes and supports long-term management. When used for MDD, it contributes to easing the overall symptom load when depressed mood remains persistent despite standard antidepressant use.

“This medication assists with maintaining functional stability and contributes to improved comfort during symptomatic periods.”

Quick Fact: Relief for Psychotic Symptoms The medication is commonly used to help with managing symptoms that interfere with daily functioning in Schizophrenia, which supports patients during episodes of heightened discomfort. The system’s unique digital component plays a role in managing long-term treatment plans by providing verifiable data on adherence.

Eligibility and Restrictions for Use

Abilify Mycite (aripiprazole tablets with sensor) is a prescription medicine approved for use in adults for specific psychiatric conditions.

Approved Uses (Who Can Use)

This medication is indicated for the treatment of adults with:

  • Schizophrenia
  • Bipolar I Disorder: For the acute treatment of manic and mixed episodes (alone or as an add-on to lithium or valproate) and for maintenance treatment (alone or as an add-on).
  • Major Depressive Disorder (MDD): As an adjunctive treatment to an antidepressant medication.

Patients must be willing and able to use the entire digital system, including wearing the sensor patch and having a compatible smartphone to access the app and share information with their healthcare provider.

Contraindications and Warnings (Who Cannot Use or Should Use with Caution)

Abilify Mycite must not be used by individuals who have a known hypersensitivity or allergic reaction to aripiprazole or any of the inactive ingredients. Additionally, the drug is not approved for:

  • Elderly patients with dementia-related psychosis, as this population has an increased risk of death when treated with antipsychotic drugs.
  • Pediatric patients (under 18 years of age), as the safety and effectiveness have not been established.

The system is not recommended for real-time monitoring of drug ingestion or during an emergency, as detection can be delayed or may not occur.

What should I know about interactions with other medicines?

The interaction profile of Abilify Mycite (aripiprazole tablets with sensor) is defined primarily by its metabolism through the liver enzymes Cytochrome P450 (CYP) 2D6 and CYP3A4. Co-administration with certain medicines requires specific dose adjustments to manage the resulting change in the concentration of aripiprazole and its active metabolite, dehydro-aripiprazole.

Metabolically-Driven Interaction Requirements

Interacting Product Category Effect on Aripiprazole Exposure Required Regulatory Action (General)
Strong CYP2D6 Inhibitors (e.g., quinidine, fluoxetine, paroxetine) Increases exposure Dose reduction is required
Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin, itraconazole) Increases exposure Dose reduction is required
Strong CYP3A4 Inducers (e.g., carbamazepine, rifampin) Decreases exposure Dose increase is required

For patients who are known poor metabolizers of CYP2D6, the required dose of aripiprazole is already reduced, and a further reduction is needed if a strong CYP3A4 inhibitor is co-administered. The official regulatory documents mandate these dose adjustments to ensure appropriate drug levels and are not general safety advice.

Mechanism of Action

The mechanism of action for Abilify Mycite is attributed to its active compound, aripiprazole, an atypical agent that interacts with multiple neurotransmitter receptors in the central nervous system. Aripiprazole functions primarily as a partial agonist at the dopamine D2 and serotonin 5-HT1A receptors. This interaction confers a stabilizing effect: it produces a submaximal functional response at these sites while simultaneously competing with endogenous full agonists.

Furthermore, the compound acts as an antagonist (blocker) at the serotonin 5-HT2A receptors. This distinctive multi-receptor profile leads to the modulation of dopaminergic and serotonergic signaling pathways in key brain circuits. This pharmacological activity influences neuronal firing patterns and neurotransmitter release dynamics, thereby adjusting the intracellular signaling cascades to achieve a normalization of activity within the affected neural systems.

Dosage and Administration Information

How to Use Abilify Mycite: Administration Guidelines

Abilify Mycite is an oral tablet with sensor intended for once-daily use, with administration governed by specific rules due to its unique design as a drug-device combination. The medicine can be taken with or without food.

Administration and Procedural Requirements

Because the tablet contains an embedded sensor, it must be swallowed whole and must not be divided, chewed, or crushed. Proper use involves wearing a complementary Mycite Patch and utilizing the Mycite App to track and record the date and time of ingestion. In instances where the digital system does not detect the ingestion of the tablet, the dose is not repeated.

Standard Dosing Regimens

Dosage is determined by the patient's condition and is administered once daily. Doses are established within defined ranges, typically starting lower and adjusting upward over time. Adjustments for Schizophrenia and Bipolar I Disorder are generally made at intervals of 2 weeks, while adjustments for Adjunctive Major Depressive Disorder occur at intervals of no less than 1 week.

Indication Initial Dose Maximum Dose
Schizophrenia 10 mg or 15 mg/day 30 mg/day
Bipolar I Disorder 15 mg/day (Monotherapy) 30 mg/day
Major Depressive Disorder (Adjunctive) 2 mg or 5 mg/day 15 mg/day

Population and Concomitant Use Adjustments

Dose modifications are utilized when certain medications are co-administered, or in the case of CYP2D6 poor metabolizers. For example, co-administration with strong CYP2D6 or CYP3A4 inhibitors involves halving the usual dose, while strong CYP3A4 inducers involve the dose being doubled over one to two weeks. These protocols are based on the activity of the aripiprazole core ingredient.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Abilify Mycite

The research base for Abilify Mycite involves two components: the established clinical trials for the drug, aripiprazole, and the specific technical studies performed to validate the performance of the integrated digital sensor system. The following sections describe the available evidence for the approved uses.

Evidence for Use in Schizophrenia

The core evidence for using the aripiprazole drug component in adults with Schizophrenia was studied for how acute symptom patterns changed over time. This research included historical Randomized Controlled Trials (RCTs) where symptom intensity and changes over time were the primary outcomes monitored. The RCTs supporting the drug component reported measurements of symptom scores compared to control conditions. However, the available research is limited by the fact that there are no RCTs directly comparing the digital medicine system to the non-digital drug to determine if the tracking feature specifically influences these clinical outcomes.

Evidence for Use in Bipolar I Disorder

The research for the aripiprazole drug component in Bipolar I Disorder was studied for both the acute treatment of manic and mixed episodes and for research exploring long-term patterns of stability. Acute treatment studies reported how symptoms evolved in the observed populations compared to control conditions. The digital system itself has not been established through clinical trials to improve adherence or modify the dosage for this condition.

Research on the Digital Medicine System Performance

Human factors studies and open-label observations were conducted to determine the accuracy of ingestion detection by the sensor and the reliability of the system. Studies reported a high technical accuracy in detecting when the tablet was swallowed. However, core technical studies do not determine whether the use of this tracking feature improves patient adherence or modifies clinical outcomes, which is a key limitation noted in the official regulatory statement.

What Remains Uncertain and Areas for Future Research

Certainty remains low regarding the specific clinical impact of the digital tracking feature. A major research limitation is the absence of comparative evidence (RCTs) to determine if using the Abilify Mycite system leads to better clinical outcomes than using the non-digital tablets. Furthermore, the product has not been established in pediatric patients and is not approved for use in older adults with dementia-related psychosis.

Frequently Asked Questions (FAQ)

Common questions about Abilify Mycite (FAQ)

Q: Can I drink alcohol while taking this medication?

According to official product information, combining this medication with alcohol may increase the risk of central nervous system (CNS) side effects. These effects include increased drowsiness, dizziness, difficulty concentrating, and decreased awareness. Official warnings note that combining the medication with alcohol may increase the risk of severe sedation and breathing problems.

Q: What should I do if I miss a dose?

Official patient information generally advises that if a dose is missed shortly after the scheduled time, it may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, product information advises to skip the missed dose and return to the regular dosing schedule. Regulatory labeling cautions against taking two doses at the same time to compensate for a missed dose.

Q: Is it safe to use this medication during pregnancy or while breastfeeding?

Regulatory documents state that use during pregnancy may cause harm to the fetus. Official product information typically advises the use of effective contraception for women of childbearing potential while receiving this treatment. Breastfeeding is generally discouraged, as the active ingredient passes into breast milk and the potential effects on a nursing infant are not established.

Q: Does it cause weight gain or swelling?

Regulatory documents list swelling of the hands, arms, legs, or feet (known as peripheral edema) as a common side effect of this medication. Weight gain is also frequently reported in official product information. The presence of severe or concerning swelling should prompt consultation with a healthcare professional.

Q: Can children use this medication?

Official regulatory documents indicate that there is limited information to recommend the use of this medication in children under the age of 18 years for its approved uses. Safety and effectiveness information primarily covers adult patients. Any decision regarding the use of this medicine in patients under 18 years of age should be based on the judgment of a qualified healthcare professional.

Q: How should I stop taking this medicine?

Regulatory warnings caution against immediately stopping this medication. The official product labeling states that discontinuation should be done gradually, usually over a minimum period of 1 week or more, as determined by a doctor. Abruptly stopping this medicine can increase the risk of withdrawal symptoms, such as anxiety, insomnia, nausea, or seizures.

How should Abilify Mycite be stored and disposed of?

Storage and Disposal of Abilify Mycite

Official regulatory labeling dictates specific storage and disposal requirements for all components of the Abilify Mycite system.

Storage Conditions

Abilify Mycite tablets with sensor must be stored at controlled room temperature, specifically between 68 F to 77 F (20 C to 25 C). The associated MYCITE Patch has a defined storage range of 41 F to 81 F (5 C to 27 C). Both the tablets and the patch must be kept dry and protected from high humidity to maintain the stability of the drug and the digital components.

Handling and Disposal

The medicine and all its components must be kept out of the reach of children. The MyCite Pod is explicitly intended for continuous use and must NOT be disposed of. Unused or expired Abilify Mycite tablets and used patches must be disposed of according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUSA

Equivalent of Abilify Mycite found in:

A-Z Index: